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Abstract
Background: This multicenter prospective study of invasive candidiasis (IC) was carried out to determine the risk factors
for, incidence of, clinical and laboratory features, treatment and outcome of IC in infants of birth weight <1250 g.
Methods: Neonates <1250 g with IC and their matched controls (2:1) were followed longitudinally and descriptive
analysis was performed. Survivors underwent neurodevelopmental assessment at 18 to 24 months corrected age.
Neurodevelopmental impairment (NDI) was defined as blindness, deafness, moderate to severe cerebral palsy, or a
score <70 on the Bayley Scales of Infant Development 2nd edition. Multivariable analyses were performed to determine
risk factors for IC and predictors of mortality and NDI.
Results: Cumulative incidence rates of IC were 4.2%, 2.2% and 1.5% for birth-weight categories <750 g, <1000 g,
<1500 g, respectively. Forty nine infants with IC and 90 controls were enrolled. Necrotizing enterocolitis (NEC) was the
only independent risk factor for IC (p = 0.03). CNS candidiasis occurred in 50% of evaluated infants, while congenital
candidiasis occurred in 31%. Infants with CNS candidiasis had a higher mortality rate (57%) and incidence of deafness
(50%) than the overall cohort of infants with IC. NDI (56% vs. 33%; p = 0.017) and death (45% vs. 7%; p = 0.0001) were
more likely in cases than in controls, respectively. IC survivors were more likely to be deaf (28% vs. 7%; p = 0.01). IC
independently predicted mortality (p = 0.0004) and NDI (p = 0.018).
Conclusion: IC occurred in 1.5% of VLBW infants. Preceding NEC increased the risk of developing IC. CNS candidiasis is
under-investigated and difficult to diagnose, but portends a very poor outcome. Mortality, deafness and NDI were
independently significantly increased in infants with IC compared to matched controls.
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Background
The clinical course, including antifungal prophylaxis and
treatment of neonatal invasive candidiasis (IC) has been
well described in the literature in a number of studies. Al-
though the serious nature of this infection with respect to
morbidity and mortality has been described, prospective
studies on neurodevelopmental outcome, especially with
comparison to a similar pre-term uninfected cohort, have
been much less common [1-7]. An early retrospective study
of forty six extremely low birth weight (ELBW, <1000 g) in-
fants with Candida sepsis or meningoencephalitis reported
a significantly higher incidence of short term morbidity
(retinopathy of prematurity, chronic lung disease and peri-
ventricular leukomalacia), in addition to a higher incidence
of adverse neurological outcomes at two years of age com-
pared to ELBW infants without invasive candidiasis [1].
This was followed by a large US prospective study in 2004
of ELBW infants, which reported poor neurodevelopmental
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outcome as a sequel to neonatal infections in general, in-
cluding unspecified fungal infections [2]. In the United
Kingdom, a national prospective surveillance study of inva-
sive fungal infection (IFI) in very low birth weight infants
(VLBW, <1500 g), published in 2006, showed higher mor-
tality in late neonatal and post-neonatal deaths in ELBW
infants with IFI compared to those without [3]. The large,
landmark US prospective cohort study, published by Benja-
min et al. in 2006, reported high rates of morbidity, mortal-
ity and neurodevelopmental impairment (NDI) in ELBW
infants with IC [4]. In a more recent publication of the
same prospective cohort at a later time period, Adams-
Chapman et al. showed that ELBW infants with Candida
sepsis or meningitis had a higher risk of death or NDI than
uninfected unmatched ELBW infants obtained from an-
other registry, but not of NDI as an isolated outcome [5].
The rate of death or NDI in the latter two studies was 59
and 73%, respectively [4,5]. The same research group con-
ducted a retrospective analysis of the infants within their
database who were managed between 2004 and 2007, and
showed that empiric antifungal therapy resulted in im-
proved survival without NDI (as a combined outcome, but
not as individual outcomes) in ELBW infants with IC [6].
In a recent retrospective study comparing outcomes in neo-
natal invasive candidiasis to those in infants with gram
negative sepsis, the authors showed that the rate of death
or NDI following candidiasis was 48% [7], though this did
not differ from the rate in the group with gram negative
sepsis. To control for the many factors influencing the
manifestation of disease and outcome in preterm neonates,
we conducted a prospective, multicenter study of IC in
Canadian infants with a birth weight <1250 g, where each
case was matched to two controls by gestational age, birth
weight, gender and institution of origin. We determined
the incidence, risk factors, laboratory features, treatment
and mortality of IC, and then followed the surviving cohort
longitudinally to assess neurodevelopmental outcome at a
corrected age of 18 to 24 months.
Methods
Study design
The study was conducted in 13 level III NICUs in
nine Canadian cities under the auspices of the
Paediatric Investigators Collaborative Network on In-
fections in Canada (PICNIC) from 2001–2006 (re-
cruitment in the first three years, follow-up extending
to 2006), and approved by each Institutional Ethics
Review Board:
 Hospital for Sick Children Research Ethics Board
 Mount Sinai Hospital Research Ethics Board
 University of Alberta Heath Research Ethics Board
 Conjoint Health Research Ethics Board, University
of Calgary
 Research Ethics Board, Sunnybrook and Women’s
College Health Sciences Centre
 Izaak Walton Killam Research Ethics Board
 Children’s Hospital of Eastern Ontario Research
Ethics Board
 The University of British Columbia/Children’s and
Women’s Health Centre of British Columbia
Research Ethics Board
 Biomedical Research Ethics Board, University of
Saskatchewan
 Comité d’éthique de la recherché, CHU St-Justine
 Ethics Board of the Montreal Children’s Hospital
 Hamilton Health Sciences/Faculty of Health
Sciences Research Ethics Board
 Research Ethics Board of the Jewish General Hospital
No attempt was made to alter the standard of care of-
fered at each center. Routine prophylaxis against IC in
high risk infants was not practiced at any center during
the course of this study. Definitions used in the study are
listed in Table 1.
In Phase 1 of the study, infants with birth weights <1500 g
satisfying inclusion criteria for IC were identified through ac-
tive laboratory and clinical surveillance. Those that
weighed <1250 g were matched with uninfected controls
and studied to determine risk factors for acquisition of IC,
mortality, and clinical and laboratory features of infection.
In Phase 2, the surviving cohort of cases and controls was
followed prospectively and assessed for neurodevelopmen-
tal outcome at a corrected age of 18 to 24 months.
Inclusion criteria
Infants with birth weights <1250 g who were less than
90 days of chronological age and had invasive candidiasis,
defined as a positive Candida culture from a sterile body
site (excluding urine), or histopathological, ophthalmo-
logic or autopsy evidence of Candida infection. In a previ-
ously published report, we described the clinical and
mortality outcome in infants with isolated Candida UTI
identified during the 3 year study recruitment period [8]
These infants were not followed beyond discharge to de-
termine long term outcome so are not included in the
current study. For the current study, the enrolment date
(or day of onset) for each case was the date of the first
positive culture from a sterile body site, or the date of
diagnosis for cases diagnosed at autopsy, by histopath-
ology or by ophthalmologic examination. For cases of con-
genital candidiasis, in which Candida chorioamnionitis
was present, the onset date was considered to be the date
of birth.
Two controls without IC were matched to each case by
birth weight ± 100 g, gestational age ± 6 days, gender and
institution of origin. Controls were required to have sur-
vived at least until the chronological age of the respective
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case at the date of onset of IC. Controls had to have been
in the NICU within 12 months of the date of enrolment of
the case. Control subjects that developed IC after enrol-
ment were re-enrolled as cases, and new controls were en-
rolled for the original case.
Incidence
Data on the incidence of invasive candidiasis were col-
lected for subjects with birth weight <1500 g and strati-
fied into three groups: <750 g, <1000 g and <1500 g.
Incidence data were aggregated for each birth weight
category from 11/13 NICUs during the first two years of
the study, for which we had full surveillance data.
Risk factor analysis for development of IC and mortality
Matched cases and controls were analysed for the presence
of possible risk factors prior to the onset of IC (or the
equivalent day of life for the control), such as central ven-
ous catheter use, necrotizing enterocolitis, gastrointestinal
surgery, parenteral nutrition, duration of intubation, and
use of third generation cephalosporins, broad spectrum an-
tibiotics, histamine receptor antagonists, theophylline or
systemic steroids.
In a separate unconditional analysis, we explored the
role of factors such as gestational age, birth weight, IC,
Candida CNS infection, necrotizing enterocolitis (NEC)
and intraventricular haemorrhage on mortality outcome.
Outcome measures
For Phase 2, the primary outcome was neurodevelop-
mental impairment (NDI). A secondary outcome was mor-
tality and/or NDI. Vision, hearing, mental and motor
development were assessed at a corrected age of 18 to
24 months by trained staff blinded to case/control status.
The Bayley Scales of Infant Development 2nd ed. (BSID-II)
[9] were the usual standard for outcome measurement. The
Vineland Adaptive Behaviour Scales [10] and Receptive-
Expressive Emergent Language Scale (REEL) [11] were ad-
ministered to infants with developmental delay that was
too severe to permit assessment by other methods. For in-
fants that could not be assessed by the Vineland or REEL
scales, growth, vision and hearing were measured. The raw
scores of the BSID-II generated the mental developmental
index (MDI) and psychomotor developmental index (PDI),
with a standardized mean value of 100, and a standard de-
viation (SD) of 15. Scores <2 SD below the mean were con-
sidered to be indicative of moderate to severe delay.
Statistical analysis
It was determined that a sample size of 45 cases was re-
quired to allow detection of a significant difference
(p <0.05) between cases and controls with 80% power,
assuming that those at risk of IC would demonstrate a
two-fold higher occurrence of risk factors over the base-
line occurrence of 10% in the general VLBW population.
Table 1 Study definitions
Condition Definition
Congenital candidiasis IC within the first 7 days of life
Severe intraventricular hemorrhage (IVH) Any IVH event≥ grade 2
Definite CNS candidiasis Positive CSF or brain culture or yeast forms on histopathology of brain
Probable CNS candidiasis Positive blood culture for Candida plus at least one of:
CSF WBC count >25 x 106/L in a non-bloody CSF
CSF protein ≥2.0 g/L
CSF/serum glucose ratio <0.5
Head ultrasound compatible with CNS candidiasis
Cerebral palsy (CP) A non-progressive disorder characterized by abnormal tone in one or more
extremities and abnormal control of movement and posture
Moderate to severe CP Not yet walking at assessment
Severe CP Unable to sit
Blindness Visual acuity <20/200 in either eye
Visual impairment Any visual deficit correctable with glasses
Deafness Hearing deficit requiring hearing aids or cochlear implants
Hearing impairment Any hearing deficit not requiring hearing aids or implants
Neurodevelopmental impairment Any of the following: blindness, deafness, moderate to severe cerebral palsy,
or score <70 in PDI or MDI of the BSID-II
Candida infection contributing to death Any of the following: death occurring within 48 hours of a positive culture of Candida
from a sterile site, death occurring within 48 hours of commencing appropriate antifungal therapy,
or documented microbiological or histopathological evidence of Candida infection in a normally
sterile site at autopsy
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Descriptive statistics, frequency distributions and percent-
ages were calculated for the treatment variables in cases,
the outcome variables and other covariates of interest. Uni-
variate conditional logistic regression was conducted to
examine potential risk factors for the development of can-
didiasis as well as to determine whether mortality, NDI or
both were associated with IC. Covariates demonstrating p
values < 0.2 were selected for entry into the corresponding
multivariable conditional logistic regression model. When
it was found that the high mortality rate of infants reduced
the number of surviving matched pairs for multivariable
analysis, an unmatched analysis was performed on the sur-
viving cohort. An unmatched analysis was also conducted
to determine factors associated with mortality. Multivari-
able logistic regression analyses were used to determine the
predictors of mortality as well as NDI at 18 to 24 months.
Results were reported as odds ratios. Congenital cases and
their controls were excluded from the analysis of post-natal
risk factors for developing IC, but not from the long-term
outcome analysis. Survival curves for cases and controls
were estimated using Kaplan Meier analysis and the log-
rank test was used to determine whether the difference
in survival was significant. SAS (version 9.1; SAS Insti-
tute Inc., Cary, NC) was used for the statistical analysis. A
p-value of <0.05 was considered statistically significant.
Results
Incidence
The two year cumulative incidence rates of IC by birth
weight were 1.5% for infants <1500 g (95% CI: 0.09-3.26),
2.2% for infants <1000 g (95% CI: 1.02-3.39), and 4.2% for
those <750 g (95% CI: 1.23-7.66).
Phase 1 demographics
We enrolled 49 infants with IC satisfying inclusion criteria
and 90 controls. Only one eligible control per case could
be found for eight of the enrolled cases. At enrolment, the
median gestational age was 25 weeks (range 23–30). The
median chronological age at onset was 14 days (range 0–
84) for all cases, but was 20 days (range 9–84) when con-
genital cases were excluded (Table 2). Male to female ratio
was 1.9:1. The mean birth weight was 748 ± 158 g. Cases
were not significantly different from controls with respect
to demographic and antenatal data, with or without the 15
congenital cases (Table 2).
Microbiology
Candida species were isolated in 47 cases from sterile
site specimens [blood alone (n = 30); blood and other
sterile sites (n = 14), and sterile sites other than blood
(autopsy brain and urine (1), autopsy lung (1), periton-
eal fluid (1)). Additionally, 5 of the 49 infants also had
placental tissue or amniotic fluid isolates of Candida. In
the two cases not confirmed by culture, there was
confirmatory histopathology from brain tissue obtained
at autopsy, and from a resected segment of ileum in an
infant who had surgical intervention for NEC with in-
testinal perforation.
Four of 49 cases (8%) were not detected until autopsy
despite all having had at least one blood culture in the
week prior to death. These included two cases of CNS
candidiasis, one of invasive pulmonary candidiasis and
one of Candida peritonitis. Twenty-six (53%) cases were
due to C. albicans, 14 (29%) to C. parapsilosis, 4 (8%) to
C. tropicalis, one to each of C. guilliermondii, and C. glab-
rata and one dual infection with C. tropicalis (blood) and
C. parapsilosis (CSF).
Disease classification
CNS candidiasis occurred in 14 of 28 (50%) infants that
had spinal fluid or autopsy evaluation yielding an overall
rate of 29% (14/49). Definite CNS candidiasis was present
in six cases by CSF culture (n = 3) or autopsy brain cul-
ture/histopathology (n = 3), and probable CNS candidiasis
in eight cases based on a positive blood culture plus CSF
pleocytosis (n = 5) and/or abnormal CSF chemistry (n = 3).
Candidemia occurred in 44/49 (90%) cases, of which 14
(32%) had Candida spp. identified from at least one other
sterile site. Candida urinary tract infection occurred in
five candidemic infants and preceded one case of CNS
candidiasis. Candida peritonitis was documented in 3 in-
fants; two had bowel perforation as a consequence of
NEC. Congenital candidiasis was diagnosed in 15 of the
49 cases (31%). Six of the 49 cases showed evidence of ex-
tensively disseminated disease with spread to more than
three organs documented at autopsy.
Treatment
Forty-five of 49 (92%) infants received antifungal therapy;
the remaining four infants died before therapy was insti-
tuted. Thirty-two (71%) of the 45 treated infants com-
menced therapy empirically or within 48 hours of diagnosis
(Table 3). Of the 45 treated infants, 25 (56%) received a sin-
gle antifungal agent; amphotericin B (n = 24) or fluconazole
(n = 1). Twenty (44%) received multiple drugs, of which 7
received two (n = 6) or more (n = 1) sequential antifungal
drugs and 13 received combination therapy. Combination
therapy consisted of amphotericin B plus 5-fluorocytosine
(5-FC) in 8 infants (18%), amphotericin B plus fluconazole
in 3 infants (7%) and all 3 drugs in 2 infants (4%). Conven-
tional amphotericin B was included in 44/45 (98%) treat-
ment regimens. Ten (23%) cases were later switched to a
lipid formulation of amphotericin B (liposomal amphoteri-
cin B (n = 4); amphotericin B lipid complex (n = 3) and an
unspecified formulation (n = 3)).
Conventional amphotericin B was prescribed at start-
ing doses of 0.25-0.49 mg/kg/d (n = 20), 0.5-0.9 mg/kg/d
(n = 6) and 1–1.3 mg/kg/d (n = 18) whereas the lipid
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formulations of amphotericin were dosed at 3 to 6 mg/
kg/d in the 10 cases that received this drug. Fluconazole
was prescribed at doses ≥ 6.0 mg/kg/d. Dosing of 5-FC
was at an average dose of 75 mg/kg/d. Forty-three (96%)
of all treated children achieved adequate doses of anti-
fungal therapy within the first 48 hours of commencing
treatment.
Of the 14 cases with CNS candidiasis, 8 received multi-
drug therapy consisting of amphotericin B plus 5-FC (n =
4), amphotericin plus fluconazole (n = 1), amphotericin
followed by fluconazole (n = 2) and all 3 drugs (n = 1).
Three of 8 cases died in this group compared to 5/6 in the
group that received amphotericin B alone.
Mortality
Death occurred in 22 (45%) cases versus 13 (14%)
matched controls, [OR = 6.00 (2.38 – 15.11); p = 0.0001].
The survival curve was significantly different for cases and
controls (p = 0.0001) (Figure 1). Candidiasis was a contrib-
uting factor to death in 19 (86%) fatal cases. Death oc-
curred within 3 days of diagnosis in 7 (32%) cases and
within 7 days of diagnosis in 10 (45%) cases.
Overall mortality rate among the 45 treated infants
was 18/45 (40%) and did not differ significantly for treat-
ment onset prior to or within 48 hours of diagnosis (14/
32 (44%); p = 0.82); achievement of adequate dosing
within 48 hours of treatment onset (17/39 (44%); p =
0.83); use of single drug therapy (14/25 (56%); p = 0.22);
or use of empiric therapy (3/8 (38%); p = 1.00) (Table 3).
Risk factors
NEC was the only independent risk factor for IC identified
(adjusted odds ratio 4.81 [95% CI: 1.14-20.41]; p = 0.03)
(Table 4). Factors associated with mortality in the un-
matched analysis included IC (p = 0.0002), gestational age
(p = 0.012), NEC (p = 0.006), any CNS infection (p =
0.0009), CNS candidiasis (p = 0.013) and either severe intra-
ventricular haemorrhage (IVH) or periventricular leukoma-
lacia (PVL) (p = 0.001). Mortality was not associated with
shock requiring inotropic support at enrolment (p = 0.83)
or gastrointestinal surgery (p = 0.05). After adjusting for se-
vere IVH or PVL, IC (OR = 3.71 [3.71- 9.11]; p = 0.004),
NEC (OR= 6.95 [2.27-21.30]; p = 0.029) and gestational age
(OR = 0.60 [0.40-0.88]; p = 0.010) remained independent
predictors of mortality.
Phase 2 demographics
Of the 104 surviving infants (27 cases, 77 controls), there
were 3 infants who were lost to follow-up, resulting in a
total of 25/27 (93%) surviving cases and 76/77 (99%)
Table 2 Demographic and perinatal features in cases and controls
Features number (%) or
mean ± SD or median (range)
unless otherwise stated








matched analysisN = 49 N = 90 N = 34 N = 62
Singleton 35 (71) 71 (79) 0.32 26 (77) 50 (81) 0.63
Vaginal delivery 29/49 (59) 50/89 (56) 0.73 16 (47) 31 (51) 0.72
Male 32 (65) 59 (66) 0.97 25 (74) 45 (73) 0.92
White 21/44 (48) 52/87 (60) 0.56 15/31 (48) 33/59 (56) 0.86
Black 7 (16) 13 (15) 1.00 5 (16) 10 (17.0) 0.99
Hispanic 4 (9) 5 (6) 0.92 3 (10) 5 (8) 0.97
Other 12 (27) 17 (19) 0.60 8 (26) 11 (19) 0.63
Mean birth weight (g) 748 ± 159 755 ± 146 0.80 790 ± 162 792 ± 151 0.93
Mean head circumference at birth (cm) 22.9 ± 1.6 23.3 ± 1.9 0.33 23.5 ± 1.6 23.5 ± 1.3 0.93
Mean length at birth (cm) 32.1 ± 2.2 32.9 ± 2.7 0.14 32.5 ± 2.3 33.0 ± 2.4 0.37
Median gestational age (weeks) 25 (23–30) 25.5 (23–30) 0.73 25.5 (23–30) 25.5 (23–30) 0.70
Respiratory distress syndrome 41 (84) 83 (92) 0.35 26 (77) 56 (90) 0.23
Gastrointestinal disorders other than NECa 2 (4) 1 (1) 0.23 2 (6) 1 (2) 0.26
NEC 12 (24) 8 (9) 0.008 12 (35) 6 (10) 0.01
PDA or other congenital heart diseaseb 37 (76) 63 (70) 0.67 27 (80) 42 (68) 0.25
Intrauterine growth retardation 3 (6) 4 (4) 1.00 3 (9) 4 (6) 1.00
Median age at enrolment (days) 14 (1–84) 14 (0–84) 1.00 20 (9–84) 16 (3–84) 0.89
Median time from admission
to death or discharge) (days)
71 (3–492) 89 (1–165) 0.54 91 (3–492) 79 (1–142) 0.09
Abbreviation: PDA, patent ductus arteriosus.
aAll required gastrointestinal surgery and included imperforate anus and jejunal perforation.
b36/37 cases and all 63 controls had only PDA.
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surviving controls that had long-term follow-up. At
follow-up assessment, cases were not significantly different
from controls in demographic characteristics (Table 5).
Developmental assessment
Twenty three of 25 (92%) surviving cases and 70/76 (92%)
surviving controls had neurodevelopmental assessments
completed. Formal testing was not possible in another 2
cases and 3 controls because they had severe developmen-
tal delay. Three controls were lost to follow-up.
Neurodevelopmental morbidity
NDI occurred in 15 (56%) cases versus 25 (33%) controls
(p = 0.017; Table 4) and was not significantly different
for treatment variables examined (p > 0.05; Table 3).
When the analysis was restricted to only those surviving
cases in which the matched controls survived, we found
that cases were still more likely than matched controls
to develop NDI (10/19 (53%) cases versus 11/38 (29%)
controls; OR = 4.81 [1.32-17.56]).
Of the four survivors of CNS candidiasis that were avail-
able for follow-up, two (50%) had NDI. Deafness occurred
more often in IC cases than controls (p = 0.01) but among
the seven cases with documented deafness, only two
(28.6%) had documentation of CNS candidiasis. Of note,
aminoglycoside use did not differ between cases [5/7
(71%)] and controls [3/4 (75%); p = 0.06] with deafness. Al-
though mean and median BSID-II scores were not signifi-
cantly different between cases and controls, more cases
than controls had BSID-II scores < 2 SD below the mean
[13/23(57%) vs. 23/70 (33%); p = 0.044], indicating moder-
ate to severe delay (Table 5).
Factors predicting neurodevelopmental impairment
Gestational age (p = 0.015) and IC (p = 0.017) were sig-
nificantly associated with NDI, while CNS candidiasis
(p = 0.62), gender (p = 0.75), oxygen requirement at
36 days (p = 0.08), head ultrasound abnormality (p = 0.10),
severe IVH/PVL (p = 0.20), ROP > stage 2 (p = 0.62) and
any CNS infection (p = 0.18) were not, in the univariate
analysis. After adjusting for any CNS infection and oxygen
requirement at 36 days, IC (OR =3.48 [1.24-9.75]; p =
0.018) and gestational age (OR = 0.57 [0.38-0.87]; p =
0.008) remained predictors of NDI. Switching any CNS in-
fection for severe IVH/PVL in the model resulted in similar
results, with IC (p = 0.19) and gestation (p = 0.007) as the
only independent predictors. Death or NDI was more likely
in infants with IC than their matched controls (OR = 5.03
[2.01-12.75]; p = 0.001).
Discussion and conclusions
Our findings demonstrate that invasive candidiasis has a
significant adverse impact on neurodevelopmental outcome
and mortality in an infant population that is already ser-
iously at risk. Infants with IC showed a three-fold higher
mortality rate over the control population (45% vs. 14%)
and a combined death or NDI rate of 76% compared to
controls (42%, p = 0.001). The 45% mortality rate in our
study was higher than the 19 to 32% reported elsewhere
Table 3 Clinical outcome related to treatment characteristics
Treatment characteristics Death proportion (%) NDI proportion (%)
[p valuea] [p valueb]
Empiric antifungal therapy 3/8 (38) [1.00] 2/5 (40) [0.64]
Antifungal therapy commenced within 48 hours of diagnosis 14/32 (44) [0.92] 8/16 (50) [0.76]
Adequate doses attained within 48 hours of commencing antifungal therapy 17/39 (44) [0.83] 13/20 (65) [0.56]
cSingle drug therapy 14/25 (56) [0.22] 5/11 (45) [0.72]
dSingle sequential therapy 0/7 (0) [0.08] 1/6 (17) [0.17]
Received≤ 14 days of treatment 9/13 (69) [0.11] 2/4 (50) [1.00]
aReference proportion refers to proportion of deaths among infants commencing antifungal treatment =18/45 (40%).
bReference proportion refers to proportion of confirmed NDI among infants who completed therapy and were discharged =15/27 (56%).
cReceived only 1 drug for entire course of therapy.
dReceived ≥ 2 drugs over entire course, but only 1 drug administered at any given time.
Figure 1 Survival of very low birth weight preterm infants with
IC (followed to 18–24 months corrected age) is significantly
less than controls (log-rank test: chi-square 16.46; df =1; HR =
3.74 (95% CI: 1.83- 7.64); p = 0.0001). Time axis represents
chronological age and not corrected age.
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[4,12,13], but the rate of death and/or NDI was similar to
that reported by Benjamin et al. [4] and Adams-Chapman
et al. [5] using similar definitions. NDI alone occurred more
often in cases than in unmatched controls and remained
significant, with an OR of 4.81 when only matched pairs
were analysed. Unique to our study was the finding that in-
fants with IC had a significantly higher risk of NDI than un-
infected control infants, not just a higher risk of the
combined outcome of NDI and mortality. This finding es-
tablishes the role of IC in causing impaired neurological de-
velopment in low birth weight preterm infants, quite apart
from its effect on mortality. We demonstrated that IC,
along with gestational age and NEC, predicted mortality.
The frequency of deafness was higher in cases compared
to controls (28% vs. 7%). Deafness was present in 50% of
meningitis survivors with follow-up, despite similar use of
aminoglycosides in both groups. The association of hearing
impairment with IC was also documented by Benjamin
et al. [4] as well as by de Haan et al. [7]. However, in con-
trast to our study, Benjamin’s study did not show hearing
impairment in the 15 Candida meningitis survivors, and de
Haan’s study did not report on the relationship of hearing
impairment to meningitis.
Variables related to the drug, dose, timing and duration
of treatment did not affect the mortality rate in IC cases.
Prompt treatment and appropriate dosing for neonatal IC
are felt to be important management strategies to rapidly
control the progress of the infection and to improve clinical
outcome. Although we did not observe an improved out-
come in infants who were treated more quickly or dosed at
therapeutic levels more rapidly than others, we did observe
that only 71% of infants began antifungal therapy within
48 hours of the diagnosis being made. A contributing factor
was the delay in communicating the positive reports of
Table 4 Univariate and multivariable matched analysis of potential risk factors preceding enrolment in infants with
non-congenital invasive candidiasis
Factors frequency (%) or median
(range) unless otherwise stated
Cases Controls Univariate odds ratio Multivariable odds ratio
N = 34 N = 62 (95% CI) [p value] (95% CI) [p value]a
Central line present 32 (97) 60 (94) 1.41 (0.19- 10.0) -
[0.73]
Central line duration (days) 15.5 (2–37) 14 (2–56) [0.46] -
Not on enteral feeds 8 (24%) 4 (6%) 4.28 (1.08-16.54) -
[0.04]
Duration intravenous lipid (days) 16 (7–69) 15 (1–35) [0.09] 1.25 (1.01-1.56)
[0.0.049]
Duration intravenous amino acid (days) 16 (3–70) 16 (6–38) 0.12 -
NEC preceding ICb 12 (35) 6 (10) 7.04 (1.50-33.30) 4.81 (1.14-20.41)
[0.01] [0.03]
Bacterial infection including UTI 17 (50) 19 (31) 2.26 (0.96-5.36) 2.79 (0.57-13.68)
[0.10] [0.21]
Any antifungal therapy prior to IC onset 13 (35) 10 (17) 2.21 (0.71-6.85) -
[0.17]
Prior GI surgery 2 (6) 2 (3) 2.59 (0.03-33.00) -
[0.43]
H2 blocker 9 (27) 7 (11) 2.94 (0.96-9.09) 0.67 (0.13-3.46)
[0.06] [0.63]
Steroids 10 (29) 13 (21) 1.25 (0.34-4.57) -
[0.74]
Theophylline 3 (9) 3 (5) 1.56 (0.24-10.56)
[0.64]
Intubation (median days) 10 (1–71) 9.5 (1–31) 0.67 -
Broad spectrum antibiotics 26 (76) 37 (60) 1.06 (0.97-1.15)
0.20
TPN, total parenteral nutrition.
aOnly available for factors included in final model; the variable ‘not on enteral feeds’ was not included in the model because this variable overlapped considerably
with the variable NEC.
bNEC severity was at least stage 2 in 87% of affected cases and 100% of affected controls.
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histopathology and culture of the placentas from birth cen-
ters to referral centers.
The overall rate of definite or probable CNS candidiasis
documented in our study was 29%. However, when only
the infants who had lumbar punctures were considered,
CNS candidiasis occurred in 50%. Although our overall
rate of CNS candidiasis was similar to that reported in the
retrospective review by Fernandez et al. (30%) [14], it was
considerably higher than the 5% reported in the U.S co-
hort study [4]. Variation in rates of lumbar puncture and
definitions of CNS candidiasis may partly explain this dis-
crepancy. Most importantly, in our study, children with
CNS candidiasis had high rates of death (57%), NDI (50%)
and deafness (50%). However, as spinal taps were not per-
formed on 43% of infants with IC, the finding that NDI
occurred at a similar rate in IC survivors with or without
documented CNS infection, suggests that there may have
been missed cases of CNS candidiasis among those that
were not completely assessed.
We and others [14,15] have found that CSF culture is in-
sensitive for the diagnosis of CNS candidiasis; one of our
cases demonstrated evidence of florid CNS infection at
autopsy despite a negative CSF culture. This may relate
to the fact that CNS candidiasis can manifest as a multi-
focal parenchymal infection rather than as meningitis.
Our results indicate that CNS candidiasis in IC is com-
mon, is under-investigated, is difficult to diagnose, and
is devastating in its impact on the neonate. These re-
sults emphasize the need for routine CSF analysis and
other diagnostic modalities, including head imaging in
infants under investigation for this infection, or after a
positive sterile site or urine culture of Candida.
Invasive candidiasis occurred at a rate of 2.2% in ELBW
infants and 1.5% in VLBW infants, with the highest rate of
4.2% in the lowest birth weight category (<750 g). Our
rates are comparable to those reported in other studies in
the pre-prophylaxis era with rates of 2 to 8% in ELBW
and 1 to 2% in VLBW infants [4,16-18].
Necrotizing enterocolitis was the only independent risk
factor for IC. Disruption of intestinal mucosal integrity in
NEC appears to be a critical factor in facilitating the trans-
location of intra-intestinal Candida into the bloodstream
in these infants.
The IDSA guideline on the management of neonatal IC
currently recommends that in nurseries with high rates of
IC, fluconazole prophylaxis should be considered as a pre-
ventive strategy in ELBW infants [19]. Given the devastat-
ingly poor outcomes that we have described in infants with
birth weights <1250 g, our data support this recommenda-
tion, and in the face of bowel perforation or NEC, should
be considered even in infants >1250 g. At this time, how-
ever, of the centers included in our study, only one employs
routine prophylaxis for ELBW infants. Several other centers
use an individualized strategy based on risk factors.
Table 5 Demographic and neurodevelopmental characteristics of survivors at follow-up
Characteristics frequency (%)
or mean ± SD, where relevant
Cases Controls Univariate odds ratiosa P value
N = 25 N = 76 [95% CI]
Corrected age at final follow-up (months) 20.4 ± 2.9 20.5 ± 3.5 0.94
Males 19 (76) 51 (67) 1.55 [0.55-4.37] 0.46
Gestational age (weeks) 25.4 ± 1.2 25.3 ± 1.5 0.77
Birth weight (g) 763 ± 151 785 ± 150 0.53
Any hearing deficitb 7 (28) 13 (18) 1.82 [0.63-5.26] 0.26
Deafness 7 (28) 5 (7) 5.37 [1.52-18.91] 0.01
Visual impairment 6 (24) 20 (26) 0.88 [0.31-4.53] 1.00
Blindness 1 (4) 1 (3) 3.08 [0.04- 248.49] 0.44
Severe CP 2 (8) 3 (4) 2.12 [0.33-13.45] 0.60
Moderate or severe CP 6 (24) 6 (8) 3.63 [0.86-15.33] 0.067
Mean PDIc 80.5 ± 17.9 82.0 ± 16.7 0.74
[Median (range)] [83.5 (49–107)] [84.5 (49–107)] [0.71]
Mean MDIc 76.7 ± 20.5 82.1 ± 19.0 0.89
[Median (range)] [72 (49–111)] [81 (49–133)] [0.23]
BSID-II <2 SD 13/23 (57) 23/70 (33) 2.66 [1.01-6.96] 0.044
NDId 15/25 (60) 25/76 (33) 3.06 [1.20-7.77] 0.017
aOdds ratios were determined analysing the surviving cohort as unmatched cases and controls to maximize sample size and allow multivariable analysis of NDI.
bDeafness or hearing impairment.
cMDI and PDI Scores that were <50 were assigned a value of 49 to allow determination of means and medians.
dRestricting analysis to only matched pairs, using conditional logistic regression, cases were still more likely to develop NDI than their matched controls (10/19
(53%) cases versus 11/38 (29%) controls; OR = 4.81 [1.32-17.56].
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One limitation of this study is that the unexpectedly
high rate of congenital IC reduced the sample available for
risk factor analysis. This limited our ability to examine
more than 3 to 4 covariates simultaneously in the multi-
variable model and may have limited the number of fac-
tors that were identified as significant in the univariate
analysis. In addition, the high mortality rate reduced the
number of survivors remaining for neurodevelopmental
assessment, especially those with CNS candidiasis. Data
on timing of central line removal in relation to time of first
positive blood culture was not available, and prevented
analysis of the contribution of this factor to mortality.
However, our follow-up rate of 97% (101/104) allowed us
to confidently report neurodevelopmental outcome in sur-
vivors and correctly report the association of NDI with IC.
Although we have previously reported mortality out-
comes in neonates with isolated Candida UTI (25% in
ELBW, 30% in infants <1250 g and 27% in VLBW in-
fants) [8], we were not able to address NDI in this group
in our study as they did not receive long term follow-up.
Based on the data in our previous study, including in-
fants with isolated UTI would have resulted in similar
mortality rates (42% in VLBW and 45% in ELBW).
This is the first prospective multicenter study to address
risk factors and long-term outcome in neonatal candidiasis
with a matched control group. Its strict inclusion criteria,
high follow-up rate and multicenter design are significant
strengths. We identified high mortality and high rates of
neurodevelopmental impairment, including deafness, in
cases compared to controls. We also identified high rates of
CNS and congenital candidiasis and highlight the difficul-
ties of diagnosing CNS infection with confidence. Future
studies should be directed at exploring early diagnostic ap-
proaches for determining the presence of CNS candidiasis
and at treatment interventions aimed at reducing unfavour-
able outcome in neonates with invasive candidiasis.
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